MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1158/1078-0432.ccr-19-3936

Медицинская библиотека · Clinical cancer research : an official journal of the American Association for Cancer Research · 2020

A Prospective, Phase 1 Trial of Nivolumab, Ipilimumab, and Radiotherapy in Patients with Advanced Melanoma.

Postow Michael A, Knox Susan J, Goldman Debra A, Elhanati Yuval, Mavinkurve Vikram, Wong Phillip, Halpenny Darragh, Reddy Sunil K, Vado Kenya, McCabe Danielle, Ramirez Kristen Aufiero, Macri Mary, Schwarzenberger Paul, Ricciardi Toni, Ryan Aileen, Venhaus Ralph, Momtaz Parisa, Shoushtari Alexander N, Callahan Margaret K, Chapman Paul B, Wolchok Jedd D, Subrahmanyam Priyanka B, Maecker Holden T, Panageas Katherine S, Barker Christopher A

Клиническое исследование I фазыСтатьяПоддержка NIH: внешняя программаПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

PURPOSE: Preclinical data suggest that radiotherapy (RT) is beneficial in combination with immune checkpoint blockade. Clinical trials have explored RT with single-agent immune checkpoint blockade, but no trials have reported RT with the combination of nivolumab and ipilimumab.

PATIENTS AND

METHODS

We conducted a phase 1 study of patients with stage IV melanoma receiving nivolumab and ipilimumab with two different dose-fractionation schemes of RT. Patients had at least one melanoma metastasis that would benefit from palliative RT and one metastasis that would not be irradiated. Nivolumab 1 mg/kg + ipilimumab 3 mg/kg and extracranial RT with a dose of 30 Gy in 10 fractions was administered in Cohort A, and then 27 Gy in 3 fractions was administered in Cohort B. The primary outcome was safety.

RESULTS

Twenty patients were treated (10 in each cohort). The rates of treatment-related grade 3-4 adverse events in Cohort A and B were 40% and 30%, respectively. There were no grade ≥3 adverse events attributed to RT. Patients responded to treatment outside of the irradiated volume (Cohort A 5/10; Cohort B 1/9). No evaluable patients had progression of irradiated metastases. Immunologic changes were seen in the peripheral blood with increases in T-cell receptor diversity in some responding patients.

CONCLUSIONS

RT with nivolumab and ipilimumab was safe compared with historical data of nivolumab and ipilimumab alone. Immunologic effects were observed in the peripheral blood. Randomized studies are ongoing to assess whether RT increases the efficacy of nivolumab and ipilimumab.

Для цитирования: Postow Michael A, Knox Susan J, Goldman Debra A, Elhanati Yuval, Mavinkurve Vikram, Wong Phillip, Halpenny Darragh, Reddy Sunil K, Vado Kenya, McCabe Danielle, Ramirez Kristen Aufiero, Macri Mary, Schwarzenberger Paul, Ricciardi Toni, Ryan Aileen, Venhaus Ralph, Momtaz Parisa, Shoushtari Alexander N, Callahan Margaret K, Chapman Paul B, Wolchok Jedd D, Subrahmanyam Priyanka B, Maecker Holden T, Panageas Katherine S, Barker Christopher A. A Prospective, Phase 1 Trial of Nivolumab, Ipilimumab, and Radiotherapy in Patients with Advanced Melanoma.. Clinical cancer research : an official journal of the American Association for Cancer Research. 2020. DOI: 10.1158/1078-0432.ccr-19-3936.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.